Payment overview · 2025
General Payments
$1,795.21
33 reported records · 6 companies
Healthcare provider profile · identity verified
Yim Ping Cheung
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health · PATCHOGUE, NY · NPI 1477137214
Verified facts
What the public records show
CMS Open Payments records show Yim Ping Cheung received $1,795.21 in general payments during 2025 across 33 reported records.
Amgen Inc. accounted for 41.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Gemtesa, Linzess, Voquezna.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
Phathom Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VOQUEZNA as an associated drug or biological on 90302 records involving 33442 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Voquezna by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $735.71 | 41.0% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $466.34 | 26.0% | 12 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $308.74 | 17.2% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $118.71 | 6.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $114.98 | 6.4% | 7 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $50.73 | 2.8% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,795.21 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $460.71 | 6 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $308.74 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $236.23 | 10 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $228.20 | 10 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $145.50 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $118.71 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $114.98 | 7 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $50.73 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 53 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 82 | exact normalized | Medicare Part D |
| VOQUEZNA voquezna |
2025 | Voquezna | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
53 | 21 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
82 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
92 | 59 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
80 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Phathom Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | VOQUEZNA open payments reported associated product |
CMS Open Payments — General Payments 90302 supporting records · 33442 recipient NPIs · example record 1219216983 |
Voquezna · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 724 | 168 |
| Losartan Potassium | Losartan Potassium | 654 | 148 |
| Amlodipine Besylate | Amlodipine Besylate | 454 | 103 |
| Vascepa | Icosapent Ethyl | 338 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 307 | 70 |
| Omeprazole | Omeprazole | 259 | 59 |
| Famotidine | Famotidine | 251 | 77 |
| Metformin Hcl | Metformin Hcl | 230 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 202 | 48 |
| Diclofenac Epolamine | Diclofenac Epolamine | 183 | 33 |
| Metformin Hcl Er | Metformin Hcl | 167 | 35 |
| Ammonium Lactate | Ammonium Lactate | 158 | 53 |
| Raloxifene Hcl | Raloxifene Hcl | 153 | 29 |
| Trazodone Hcl | Trazodone Hcl | 152 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 142 | 40 |
| Simvastatin | Simvastatin | 133 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 130 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 123 | 27 |
| Levothyroxine Sodium | Levothyroxine Sodium | 123 | 28 |
| Montelukast Sodium | Montelukast Sodium | 115 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 114 | 28 |
| Alendronate Sodium | Alendronate Sodium | 109 | 24 |
| Ezetimibe | Ezetimibe | 107 | 29 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 105 | 57 |
| Allopurinol | Allopurinol | 101 | 18 |
| Myrbetriq | Mirabegron | 98 | 19 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 97 | 74 |
| Finasteride | Finasteride | 97 | 26 |
| Gabapentin | Gabapentin | 96 | 23 |
| Januvia | Sitagliptin Phosphate | 93 | 17 |
| Prolia | Denosumab | 92 | 59 |
| Eliquis | Apixaban | 91 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 87 | 33 |
| Bepotastine Besilate | Bepotastine Besilate | 86 | 21 |
| Linzess | Linaclotide | 82 | 17 |
| Icosapent Ethyl | Icosapent Ethyl | 81 | 26 |
| Farxiga | Dapagliflozin Propanediol | 80 | 20 |
| Meloxicam | Meloxicam | 73 | 38 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 69 | 26 |
| Azelastine Hcl | Azelastine Hcl | 64 | 19 |
| Folic Acid | Folic Acid | 63 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 63 | 14 |
| Mirtazapine | Mirtazapine | 60 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 58 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 54 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 54 | 12 |
| Mometasone Furoate | Mometasone Furoate | 54 | 15 |
| Creon | Lipase/Protease/Amylase | 53 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | 13 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 50 | 13 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 49 | 49 |
| Atenolol | Atenolol | 49 | 14 |
| Glimepiride | Glimepiride | 49 | 13 |
| Jardiance | Empagliflozin | 49 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 14 |
| Azithromycin | Azithromycin | 46 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 46 | 11 |
| Telmisartan | Telmisartan | 46 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 45 | 11 |
| Synthroid | Levothyroxine Sodium | 43 | suppressed |
| Ciclopirox | Ciclopirox | 42 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 42 | 22 |
| Donepezil Hcl | Donepezil Hcl | 39 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 36 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 36 | suppressed |
| Lidocaine | Lidocaine | 34 | suppressed |
| Rybelsus | Semaglutide | 33 | suppressed |
| Tradjenta | Linagliptin | 33 | suppressed |
| Carvedilol | Carvedilol | 31 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | 12 |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Hydrocortisone | Hydrocortisone | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 25 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 24 | suppressed |
| Restasis | Cyclosporine | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Furosemide | Furosemide | 22 | 12 |
| Lisinopril | Lisinopril | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Alprazolam | Alprazolam | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 16 |
| Donepezil Hcl Odt | Donepezil Hcl | 20 | suppressed |
| Dutasteride | Dutasteride | 20 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Ursodiol | Ursodiol | 20 | suppressed |
| Acarbose | Acarbose | 19 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 18 | suppressed |
| Gemtesa | Vibegron | 18 | suppressed |
| Prednisone | Prednisone | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Entecavir | Entecavir | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 16 | suppressed |
| Voquezna | Vonoprazan Fumarate | 16 | suppressed |
| Procto-Med Hc | Hydrocortisone | 15 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Potassium Chloride | Potassium Chloride | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Tacrolimus | Tacrolimus | 14 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 12 |
| Cyclosporine | Cyclosporine | 12 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 12 | suppressed |
| Leucovorin Calcium | Leucovorin Calcium | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Calcium Acetate | Calcium Acetate | 11 | suppressed |
| Dexilant | Dexlansoprazole | 11 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
| Tavaborole | Tavaborole | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,795.21 · 33 records | Amgen Inc. | BREZTRI, CREON, EVENITY, GEMTESA, LINZESS, OTEZLA, REPATHA, VOQUEZNA, XIFAXAN | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error